[go: up one dir, main page]

ZA200803206B - Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid - Google Patents

Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid

Info

Publication number
ZA200803206B
ZA200803206B ZA200803206A ZA200803206A ZA200803206B ZA 200803206 B ZA200803206 B ZA 200803206B ZA 200803206 A ZA200803206 A ZA 200803206A ZA 200803206 A ZA200803206 A ZA 200803206A ZA 200803206 B ZA200803206 B ZA 200803206B
Authority
ZA
South Africa
Prior art keywords
chlorosalicyloyl
sodium salt
crystalline forms
aminocaprylic acid
aminocaprylic
Prior art date
Application number
ZA200803206A
Other languages
English (en)
Inventor
Dhoot Nikhil
Bay William Elliot
Dinh Steven
Majuru Shingai
Joanne P Corvino
Doris C O'toole
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37889458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200803206(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of ZA200803206B publication Critical patent/ZA200803206B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200803206A 2005-09-19 2008-04-11 Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid ZA200803206B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71882905P 2005-09-19 2005-09-19

Publications (1)

Publication Number Publication Date
ZA200803206B true ZA200803206B (en) 2009-08-26

Family

ID=37889458

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803206A ZA200803206B (en) 2005-09-19 2008-04-11 Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid

Country Status (19)

Country Link
US (3) US8026392B2 (es)
EP (1) EP1937627A4 (es)
JP (1) JP2009508875A (es)
KR (1) KR20080049128A (es)
CN (2) CN105641686A (es)
AR (1) AR058053A1 (es)
AU (1) AU2006292337B8 (es)
BR (1) BRPI0616558B1 (es)
CA (1) CA2619673C (es)
GT (1) GT200600421A (es)
IL (1) IL189015A (es)
JO (1) JO3684B1 (es)
NZ (1) NZ566397A (es)
PE (2) PE20100241A1 (es)
RU (1) RU2507196C2 (es)
SG (1) SG165397A1 (es)
TW (1) TWI386386B (es)
WO (1) WO2007035718A2 (es)
ZA (1) ZA200803206B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603252D0 (en) * 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101557827A (zh) * 2006-08-31 2009-10-14 诺瓦提斯公司 用于口服递送的包含hgh的药物组合物
US20110039930A1 (en) 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
PT2897620T (pt) 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
ES3030918T3 (en) * 2020-05-29 2025-07-02 Sciwind Biosciences Co Ltd N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
WO2022226217A1 (en) * 2021-04-22 2022-10-27 Civi Biopharma, Inc. Oral delivery of oligonucleotides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1234561A (en) 1985-06-26 1988-03-29 Kenneth M. White Profiled body roller-reamer stabilizer
US5069419A (en) 1989-06-23 1991-12-03 Ic Sensors Inc. Semiconductor microactuator
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JPH11140064A (ja) * 1997-11-10 1999-05-25 Nippon Nohyaku Co Ltd １，２，３−チアジアゾール誘導体の製造方法及び中間体化合物
US6126140A (en) 1997-12-29 2000-10-03 Honeywell International Inc. Monolithic bi-directional microvalve with enclosed drive electric field
AU3378100A (en) * 1999-02-26 2000-09-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU4216700A (en) * 1999-04-05 2000-10-23 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
SK287697B6 (sk) 2001-06-01 2011-06-06 Novartis Ag Orálne podanie paratyroidného hormónu a kalcitonínu
SI1420827T1 (sl) 2001-08-17 2010-01-29 Novartis Ag 5-CNAC kot sredstvo za oralno dajanje fragmentov paratiroidnega hormona
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (es) 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
CA2531136A1 (en) 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
CN1809377B (zh) * 2003-07-11 2010-08-04 诺瓦提斯公司 包含微粉化形式的传送剂的口服给药药物组合物
EP2316473B1 (en) * 2003-07-23 2013-08-21 Novartis AG Use of calcitonin in osteoarthritis
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
AU2005286727A1 (en) 2004-09-23 2006-03-30 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
SG152229A1 (en) 2005-08-25 2009-05-29 Univ Arizona Stem cell fusion model of carcinogenesis
US20070048725A1 (en) 2005-08-25 2007-03-01 Arrington Ben O'mar Machine perfusion of tissue grafts for transplantation

Also Published As

Publication number Publication date
US20130303444A1 (en) 2013-11-14
WO2007035718A2 (en) 2007-03-29
CN105641686A (zh) 2016-06-08
IL189015A0 (en) 2008-08-07
TWI386386B (zh) 2013-02-21
CN101627011A (zh) 2010-01-13
KR20080049128A (ko) 2008-06-03
RU2507196C2 (ru) 2014-02-20
GT200600421A (es) 2012-03-16
TW200744993A (en) 2007-12-16
JP2009508875A (ja) 2009-03-05
IL189015A (en) 2016-09-29
US20080269108A1 (en) 2008-10-30
CA2619673A1 (en) 2007-03-29
EP1937627A4 (en) 2010-09-01
US9238074B2 (en) 2016-01-19
AU2006292337A1 (en) 2007-03-29
AR058053A1 (es) 2008-01-23
CA2619673C (en) 2018-07-10
JO3684B1 (ar) 2020-08-27
AU2006292337B8 (en) 2013-02-07
BRPI0616558B1 (pt) 2021-09-08
RU2008103699A (ru) 2009-10-27
US8431736B2 (en) 2013-04-30
EP1937627A2 (en) 2008-07-02
US8026392B2 (en) 2011-09-27
PE20100241A1 (es) 2010-04-16
WO2007035718A3 (en) 2009-06-18
NZ566397A (en) 2010-04-30
PE20070548A1 (es) 2007-07-12
US20120065128A1 (en) 2012-03-15
BRPI0616558A2 (pt) 2011-06-21
SG165397A1 (en) 2010-10-28
AU2006292337B2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
ZA200803206B (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
IL173382A0 (en) Amino acid prodrugs
HUE059645T2 (hu) Glutaminsav heterodimerei
IL187772A0 (en) Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine
ZA200804611B (en) Methods for the use of branched chain amino acids
ZA200704789B (en) Novel anthranilic acid derivative or salt thereof
ZA200707531B (en) N-(N-Sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
BRPI0716539A2 (pt) métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
SI1860098T1 (sl) Nov derivat antranilne kisline ali sol le-tega
PL1913049T3 (pl) Poliuretany wytworzone z amidów kwasów tłuszczowych zawierających grupę hydroksylową
IL184945A0 (en) Crystalline forms of pregabalin
ZA200804780B (en) Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
EP1908757A4 (en) CHOLIN SALT CRYSTAL OF AN AZULAR COMPOUND
ZA200707678B (en) Amino acid derivatives
IL187655A0 (en) Anthranilic acid derivatives
HU0401525D0 (en) New kynurenic acid amide derivatives
IL190963A0 (en) Novel processes for the preparation of piperazinly and diazapanyl benzamide derivatives
EP1714976A4 (en) AMINO ACID SEQUENCES OF THE ACTIVE PRINCIPLE OF MOSCHUS AND ITS ACETIC ACID SALT AND THE PRODUCTION AND USE THEREOF
IL175156A0 (en) Process for the preparation of gabapentin
ZA200805701B (en) Salts of styphnic acid
PL377747A1 (pl) Synteza amidu kwasu 3-(4-hydroksyfenylo) propanowego
HUP0500940A2 (en) Process for the preparation of carbidopa
GB0415076D0 (en) Process for the preparation of gabapentin
GB0420607D0 (en) Amino acid
GB0425900D0 (en) Novel pyrrolopyridine-2-carboxylic acid amide